Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adhera Therapeutics, Inc.MRNA · Entity 127789 | Chief Financial Officer | October 02, 2017 | October 06, 2017 |
| Oncotelic Therapeutics, Inc.OTLC · Entity 7822 | CFO | July 10, 2026 | July 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adhera Therapeutics, Inc.
Report date October 02, 2017 · Filed October 06, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2022-10-02 | Direct | 60,000 |
Reported balance
After 2017-10-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-10-02 · Grant · Acquired 60,000 · Balance 60,000 |
Oncotelic Therapeutics, Inc.
Report date July 10, 2026 · Filed July 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 1,500 |
Reported balance
After 2026-07-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-10 · Grant · Acquired 1,500 · Balance 1,500 F1: On July 10, 2026, the reporting person was granted 1,500 restricted stock units ("RSUs"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share. F2: The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 10, 2026, the reporting person was granted 1,500 restricted stock units ("RSUs"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share.
F2: The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 10, 2026 Filed Jul 14, 2026 20:00 UTC | Oncotelic Therapeutics, Inc. OTLC · Entity 7822 | GrantRestricted stock Units · Derivative | 1,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-033167 · ownership.xml · derivative · entry 1 Shah Amit B. · CIK 0001719077 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: Series A Preferred Stock · 1,500 shares Expires not disclosed F1 · security: On July 10, 2026, the reporting person was granted 1,500 restricted stock units ("RSUs"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share. F2 · derivative.exercise_date: The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting. F2 · derivative.expiration_date: The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting. Read SEC document |
| June 22, 2026 Filed Jun 22, 2026 20:30 UTC | Oncotelic Therapeutics, Inc. OTLC · Entity 7822 | PurchaseCommon Stock | 20,000 | $0.05 | $1,000.00 |
DisclosureSEC source: 0001493152-26-029594 · ownership.xml · nonDerivative · entry 1 Shah Amit B. · CIK 0001719077 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 378,837 F1 · date: On June 22, 2026, Amit Shah purchased 20,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.05. F1 · deemedExecutionDate: On June 22, 2026, Amit Shah purchased 20,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.05. Read SEC document |
| July 08, 2021 Filed Jul 16, 2021 21:37 UTC | Oncotelic Therapeutics, Inc. OTLC · Entity 7822 | GrantStock Options · Derivative | 698,256 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0001493152-21-017104 · ownership.xml · derivative · entry 2 Shah Amit B. · CIK 0001719077 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 698,256 Underlying: Common Stock · 698,256 shares Expires 2031-07-08 F2 · shares: Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vest immediately on date of grant. Read SEC document |
| July 08, 2021 Filed Jul 16, 2021 21:37 UTC | Oncotelic Therapeutics, Inc. OTLC · Entity 7822 | GrantCommon Stock | 298,837 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-017104 · ownership.xml · nonDerivative · entry 1 Shah Amit B. · CIK 0001719077 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 358,837 F1 · shares: Shares were issued in settlement of Restricted Stock Units granted pursuant to the Issuer's 2015 Equity Incentive Plan that vested immediately upon grant. Read SEC document |
| November 24, 2020 Filed Nov 24, 2020 22:30 UTC | Oncotelic Therapeutics, Inc. MATN · Entity 7822 | PurchaseCommon Stock | 8,220 | $0.19 | $1,561.80 |
DisclosureSEC source: 0001493152-20-022450 · ownership.xml · nonDerivative · entry 3 Shah Amit B. · CIK 0001719077 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 22:30 UTC | Oncotelic Therapeutics, Inc. MATN · Entity 7822 | PurchaseCommon Stock | 20,088 | $0.19 | $3,816.72 |
DisclosureSEC source: 0001493152-20-022450 · ownership.xml · nonDerivative · entry 2 Shah Amit B. · CIK 0001719077 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,780 Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 22:30 UTC | Oncotelic Therapeutics, Inc. MATN · Entity 7822 | PurchaseCommon Stock | 31,692 | $0.20 | $6,179.94 |
DisclosureSEC source: 0001493152-20-022450 · ownership.xml · nonDerivative · entry 1 Shah Amit B. · CIK 0001719077 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,692 Read SEC document |
| October 02, 2017 Filed Oct 6, 2017 14:55 UTC | Adhera Therapeutics, Inc. MRNA · Entity 127789 | GrantOptions to purchase common stock · Derivative | 60,000 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001719077-17-000002 · primary_doc.xml · derivative · entry 1 Shah Amit B. · CIK 0001719077 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: common stock · 60,000 shares Expires 2022-10-02 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.